. Author manuscript; available in PMC: 2010 Feb 1.

Published in final edited form as: Clin Cancer Res. 2009 Feb 1;15(3):1024–1031. doi: 10.1158/1078-0432.CCR-08-1143

Table 1.

Patient Characteristics by Urinary Cystatin B Level

	Low Cystatin B n = 30	High Cystatin B n = 17	p-value
Mean Age in years (range)	73.7 (60-89)	74.5 (46-96)	^*0.8322
Gender
Male	23 (77%)	9 (53%)
Female	7 (23%)	8 (47%)	^**0.1144
Previous TCC Bladder	23 (77%)	16 (94%)	^**0.2276
Prior Intravesical (BCG) Treatment	4 (13%)	5 (29%)	^**0.2516
Tumor Grade:
1	12 (40%)	2 (12%)	-
2	12 (40%)	5 (29%)	-
3	6 (20%)	10 (59%)	^†0.0179
Tumor Stage:
pTa	28 (93.3%)	10 (59%)	-
pT1	1 (3.3%)	3 (18%)	-
pT2	1 (3.3%)	4 (23%)	^†0.0152
Multifocality present tumor	15 (50%)	10 (59%)	^**0.7617
BCG Treatment of present tumor	3 (10%)	2 (12%)	^**1.00
Mean Follow-up (months) of Patients without Recurrence or Progression
Recurrence Analysis	24.9 (SD 11.3)	25.6 (SD 6.7)	^*0.8962
Progression Analysis	32.1 (SD 10.5)	28.6 (SD 9.0)	^*0.9084

Column percents represent proportions of patients within low cystatin B (n=30) and high cystatin B (n=17) categories

T-test

^**

Fisher’s Exact Test

^†

Chi-Square test for differences across grade and stage.